Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...
Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial ...
Cardiologists have raised this question after the disappointing results of the phase 3 OCEANIC-AF trial, in which the anti-XI peptide asundexian (Bayer) failed to demonstrate efficacy, leading to ...
Hosted on MSN12mon
Bayer's (BAYRY) Elinzanetant Meets Goals in Third Phase III StudyBayer AG BAYRY announced positive top-line ... The late-stage study, OCEANIC-AF, investigating asundexian compared with direct oral anticoagulant Eliquis (apixaban) in patients with atrial ...
Bayer AG (BAYRY) reports modest sales growth and debt reduction amid financial headwinds and strategic challenges.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results